title: Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses.
abstract: Berberine is an herbal alkaloid with various biological activities, including anti-inflammatory and antidepressant effects. Here, we examined the effects of berberine on dopamine receptors and the ensuing anti-inflammatory responses. Berberine was found to be an antagonist at both dopamine D1- and D2-like receptors and ameliorates the development of experimentally induced colitis in mice. In lipopolysaccharide-stimulated immune cells, berberine treatment modified cytokine levels, consistent with the effects of the dopamine receptor specific antagonists SCH23390 and L750667. Our findings indicate that dopamine receptor antagonists suppress innate and adaptive immune responses, providing a foundation for their use in combatting inflammatory diseases.
authors.affiliation: Department of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kawano
authors.affiliation: Department of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Japan.
authors.forename: Rie
authors.initials: R
authors.lastname: Takagi
authors.affiliation: Tsumura Research Laboratories, Tsumura & Co., Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kaneko
authors.affiliation: Department of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Japan; Allergy Center, Saitama Medical University, Japan. Electronic address: shomat@saitama-med.ac.jp.
authors.forename: Sho
authors.initials: S
authors.lastname: Matsushita
mesh_terms: D056704:Adaptive Immunity / Q000187:drug effects*; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D001599:Berberine / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000187:drug effects / Q000378:metabolism; D016264:Dextran Sulfate / Q000633:toxicity; D004195:Disease Models, Animal; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D007113:Immunity, Innate / Q000187:drug effects*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D011485:Protein Binding / Q000187:drug effects; D011725:Pyridines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D013997:Time Factors
chemical_list: D001552:Benzazepines; D016207:Cytokines; D018492:Dopamine Antagonists; C103081:L 750667; D008070:Lipopolysaccharides; D011725:Pyridines; D011758:Pyrroles; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; C534628:SCH 23390; D001599:Berberine; D016264:Dextran Sulfate
keywords: Antagonist; Autoimmune disease; Berberine; Dopamine receptors; Innate immune response; T helpers